Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPIONBreast03 in residual triple-negative breast cancer after neoadjuvant therapy
2022-002680-30Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, durvalumab, capecitabine and pembrolizumab in triple-negative breast cancer (TNBC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Invasive disease-free survival. Started Oct 2022; status: active.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-002680-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002680-30.